VAC，VAC/VII，CAV/IE: Low risk: VAC Intermediate risk: VAC/VII High risk: CAV/IE Very high risk: CAV/VIP
Study summary
The purpose is to explore the efficacy and safety of the SYSUCC-RMS regimen for pediatric RMS patients and to explore the impact of concurrent radiotherapy and chemotherapy on the survival rate of low-risk, medium risk, high-risk, and extremely high-risk patients in children.
Eligibility
Sex
ALL
Min age
0 Years
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria:
1. 0 years \< age \< 18 years old, regardless of gender;
2. Tumor patients diagnosed by histopathology or bone marrow cytology;
3. Patients are treated for the first time;
4. ECoG score ≤ 2;
5. The expected survival time is more than 8 months;
6. Patient's parent or guardian signs informed consent.
Exclusion Criteria:
1. Combined with immunodeficiency disease
2. Second tumor
Primary outcome measure(s)
The objective response rate (ORR) — Up to 1 year The ORR was calculated based on the best overall response.
disease control rate (DCR) — Up to 1 year
progression-free survival (PFS) — Up to 10 years Furthermore, we provided Kaplan-Meier plots for PFS
overall survival (OS) — Up to 10 years Furthermore, we provided Kaplan-Meier plots for OS.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.